

QUALE RUOLO DELLA VALVULOPLASTICA IN EPOCA TAVI

Paola Colombo, MD PhD

Dipartimento Cardiovascolare, Cardiologia Emodinamica

ASST Niguarda Milano

MINI CORSO INTERVENTISTICA/CARDIOCHIRURGIA

■ Responsabili esecutivi: *Corrado Lettieri (Mantova)* e *Giuseppe Tarelli (Rozzano)*

Lunedì, 27 marzo 2017

Stenosi aortica: chirurgia e TAVI

Moderatori: *Battistina Castiglioni (Varese)*, *Diego Ornaghi (Rozzano)*

- 11.40 TAVI: la tecnologia progredisce, l'esperienza degli operatori aumenta, le complicanze si riducono: quindi...
Francesco Bedogni (San Donato Milanese)
- 12.00 TAVI: tutto vero...ma non allarghiamo le indicazioni! *Carlo de Vincentiis (San Donato Milanese)*
- 12.20 Quale è il ruolo della valvuloplastica in epoca TAVI? *Paola Colombo (Milano)*
- 12.40 La valutazione dell'insufficienza mitralica associata a SAo nello screening pre TAVI: quale impatto decisionale
Maurizio Tusa (San Donato Milanese)
- 13.00 Discussione



The poster for the IX Congresso Nazionale Ecocardiografia 2017 features a central image of a stethoscope and a heart rate monitor line. The text is arranged around these elements, providing details about the congress dates, location, and organizers.

**IX CONGRESSO NAZIONALE
ECOCARDIOCHIRURGIA 2017**

27 - 28 - 29 MARZO 2017 MILANO

MILANO, 27 - 28 - 29 MARZO 2017

PROGRAMMA AVANZATO

Centro Congressi
Palazzo delle Stelline
Corso Magenta, 61
20123 Milano

DIRETTORI
ANTONIO MANTERO
GIUSEPPE TARELLI


COORDINATORI ESECUTIVI
FRANCESCO ALAMANNI
EMANUELE CATENA
GIOVANNI CORRADO
CORRADO LETTIERI



UOMO 81 ANNI

- Ipertensione, dislipidemia
- Morbo di Parkinson in trattamento
- IRC e quadro di MGUS IgM Lamda stabile
- Vasculopatia carotidea
- Coronaropatia: pregresso BPAC (AMI-IVA, AO-IVP-PL) e pregresse PTCA con DES (TC-CX-MO e IVA nativa)
- Dal 2011 SAO con FE conservata IM moderata
- Dal marzo 2016 peggioramento clinico (edemi declivi, dispnea, sincope di dubbia origine). Limitazione attività quotidiana
- Inviato in PS da curante: SAO severa FE 42% IM moderata

- Episodi confusionali durante il ricovero
- EEG tendenza addormentamento spontaneo
- Esegue valutazione con CT, ecocardiogramma e coronarografia (stenosi di MO trattata con DES)
- Episodi di macroematuria da strattoneamento di catetere




HEART TEAM

BAV PALLIATIVA

ESC GL 2012 INDICATIONS FOR BALLOON VALVULOPLASTY

Management of severe aortic stenosis



May be considered

- As bridge to AVR or TAVI in haemodynamically unstable patients
- In symptomatic severe AS who require urgent non cardiac surgery (IIbC)
- As palliative treatment if surgery is contraindicated and TAVI is not an option

Table 8. Summary of Recommendations for AS: Choice of Surgical or Transcatheter Intervention

Recommendations	COR	LOE	References
Surgical AVR is recommended in patients who meet an indication for AVR (Section 3.4) with low or intermediate surgical risk (Section 2.5 in the full-text guideline)	I	A	69,70
For patients in whom TAVR or high-risk surgical AVR is being considered, members of a Heart Valve Team should collaborate to provide optimal patient care	I	C	N/A
TAVR is recommended in patients who meet an indication for AVR for AS who have a prohibitive surgical risk and a predicted post-TAVR survival >12 mo	I	B	71,72
TAVR is a reasonable alternative to surgical AVR in patients who meet an indication for AVR (Section 3.4) and who have high surgical risk (Section 2.5 in the full-text guideline)	IIa	B	73,74
Percutaneous aortic balloon dilation may be considered as a bridge to surgical or transcatheter AVR in severely symptomatic patients with severe AS	IIb	C	N/A
TAVR is not recommended in patients in whom existing comorbidities would preclude the expected benefit from correction of AS	III: No Benefit	B	71

AS indicates aortic stenosis; AVR, aortic valve replacement; COR, Class of Recommendation; LOE, Level of Evidence; N/A, not applicable; and TAVR, transcatheter aortic valve replacement.

2012 ACCF/AATS/SCA/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement

Developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance

- High recurrence rate
- Poor prognosis (survival 1 y 50% - 3 y 20%)
- 15-25% serious complications
- **Should not be used as a substitute even as a palliative treatment**
- **No difference in long term follow up with OMT**
- **Bridge to TAVI or AVR (IIbC)**
- **To Assess clinical improvement**

Table 2 Summary of ESC¹² and AHA/ACC¹³ guidelines for the role of BAV in managing severe aortic stenosis


Indication for BAV in severe symptomatic aortic stenosis	ESC (2012)	AHA/ACC (2014)
As bridge therapy for <i>all</i> patients undergoing TAVI or AVR	x	✓
As bridge therapy for <i>haemodynamically unstable</i> patients undergoing TAVI or AVR	✓	✓
For patients requiring urgent non-cardiac surgery	✓	x
As a palliative procedure for symptomatic benefit	✓	x

AVR, aortic valve replacement; BAV, balloon aortic valvuloplasty; ESC, European Society of Cardiology; TAVI, transcatheter aortic valve implantation.

SOME HISTORY AND RESULTS

- Introduction in 1985 by A. Cribier
- Stretching of the valve's cusp and annulus, micro-rupture of calcifications and partial separation of the commissures
- Goal: increase aortic area by 40% or $> 1 \text{ cm}^2$, reduce mean gradient by 40% or $< 40 \text{ mmHg}$
- Immediate and 30 days outcome is satisfactory, perioperative mortality 3% - 30 days mortality 14%
- **Long term follow up is disappointment, as natural course**

UK procedures 2013 – procedures per month



- DURING TAVI (PRE E POST IMPLANTATION)
- BRIDGING TO ASSESS THERAPEUTIC RESPONSE
- SYMPTOM PALLIATION AND CARADIOGENIC SHOCK
- AGING

- Vascular damage
- Stroke
- AMI
- Perforation
- Tamponade
- Severe AR or MR
- Annulus rupture
- Aortic dissection
- Pump failure
- Dysrhythmia
- Emergent cardiac surgery
- mortality

PROCEDURAL RISKS




CRITERIA FOR BAV EXCLUSION

- Prosthetic aortic valve
- Active endocarditis
- Severe AR
- Significant frailty and comorbidities, so that BAV don't change quality of life
- Annular area too small or too large
- LV or LAA thrombus
- Active bleeding



MY PERSONAL OPINION: WHEN TO DO BAV

- Emergency BAV in severe AS in cardiogenic shock
- Hemodynamic instability, as bridging therapy to TAVI or AVR
- To perform an urgent non cardiac surgery
- Concomitant neoplasm requiring further diagnostics
- **Unclear AS symptoms with concomitant severe comorbidity** (eg lung disease)
- **Doubts concerning AS severity**
- Unavailability of TAVI due to logistic or economic issues
- Performance of TAVI and AVR is impossible



WHICH PTS NON SUITABLE FOR TAVI AND AVR

- Porcelain aorta
- Chest malformation
- High operative risk (STS >10)
- No anatomic criteria for TAVI (eg annulus or access)
- Life expectancy < 1 y or severe cachessia
- Very low LV EF
- LV Surgical remodelling




HOW TO REDUCE COMPLICATIONS

- CT Access evaluation and fluoroscopic guided puncture
- Proglide predeployed
- CT annulus evaluation
- Pre-shaped wires
- Use permanent PM
- Internal jugular vein for pacing
- Balloon dimension
- Sufficient operator expertise
- Tertiary centres



3D
Ex: 103237909
Se:8 +c
Volume Rendering No cut
AGRA TI PAOLO
OSPEDALE NIGUARDA
M 87 30494251
DoB: Apr 24 1929
Ex:Mar 17 2017

Immagine non GE
DFOV 34.6cm
B26f Ph:37%



No VOI
kv 100
mA Mod.
330ms
1.0mm /1.0sp
Oblique
Ex: 103237909

Se:8 +c
A: 213.4

Immagine non GE
DFOV 34.6cm
B26f Ph:37%




0.7/
kv 100
mA Mod.
330ms
1.0mm /1.0sp
Tilt: 0.0
TP37PC0867 04:01:38 PM
W = 1708 L = 259

I 665

HOW TO REDUCE COMPLICATIONS

Oblique
Ex: 103237909
Se:8 +c
L: 3.2 (col)
Immagine non GE
DFOV 9.5cm
B26f Ph:37%



0.7/
kv 100
mA Mod.
330ms
1.0mm /1.0sp
Tilt: 0.0
TP37PC0867 04:01:38 PM
W = 1708 L = 259

ROI 1 min=137 378.4mm2

AGRA TI PAOLO
OSPEDALE NIGUARDA
M 87 30494251
DoB: Apr 24 1929
Ex:Mar 17 2017




No cut
AGRA TI PAOLO
OSPEDALE NIGUARDA
M 87 30494251
DoB: Apr 24 1929
Ex:Mar 17 2017

0.7/
kv 100
mA Mod.
330ms
1.0mm /1.0sp
Tilt: 0.0
TP37PC0867 04:01:38 PM
W = 1708 L = 259

Gantry OFF

0 L 0 LAO 0 CRA

I 1026




AGRA TI PAOLO
OSPEDALE NIGUARDA
M 87 30494251
DoB: Apr 24 1929
Ex:Mar 17 2017


0.7/
kv 100
mA Mod.
330ms
1.0mm /1.0sp
Tilt: 0.0
TP37PC0867 04:01:38 PM
W = 1708 L = 259


IRP

HOW TO REDUCE COMPLICATIONS



SOME TIPS AND TRICKS







SOME TIPS AND TRICKS

WWW: 256WL: 128

(Fig. 6)

SOME TIPS AND TRICKS



SOME TIPS AND TRICKS





HEART TEAM

THANKS FOR YOUR ATTENTION

